Cancer drugs should kill tumors, not encourage their spread. But new evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone, according to researchers at Washington University School of Medicine in St. Louis.
Steven L. Teitelbaum, M.D., has been awarded a $1.71 million MERIT award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health.
Ritonavir may slow bone loss in AIDS patients.In a collaborative study initiated by their clinical colleagues, scientists at the School of Medicine have shown that the AIDS drug ritonavir suppresses the creation and activity of cells that dismantle bone, potentially slowing bone loss and lowering the risk of osteoporosis in AIDS patients. The findings may encourage clinicians to consider permanently keeping ritonavir or a similar bone-sparing drug in the changing mixture of treatments for AIDS patients.